Zhilong Huoxue Tongyu Capsule Treatment Of Acute Cerebral Infarction Clinical And Experimental Research

Objective: Zhilong Huoxue Tongyu capsule on the treatment of patients with acute cerebral infarction efficacy and safety of clinical research, and to explore their areas of rat cerebral infarction cell apoptosis.Methods: 1 Part of a Clinical: A randomized, controlled ,Parallel,trial study. Into the standard will be consistent with the object of study by a random number table: a randomized into the treatment group and the control group were studied. Case selection criteria with a total of 60 cases, of which 30 treatment group, the control group of 30 patients. TCM diagnosis, classification criterion-referenced "new Chinese medicine treatment of stroke clinical study of the guiding principles of standards". Western medicine diagnostic criterion-referenced 1995 4th National Conference cerebrovascular disease revised "various cerebrovascular disease diagnosis of cerebral infarction" in the diagnostic criteria. TCM Meridian is a type of stroke in the wind phlegm Yuzu-treatment group based therapy plus a Zhilong Huoxue Tongyu capsule four tid, and the control group used for the basis, for a two week course. Observation security, Syndrome, neurological impairment score, stroke Scale (NIHSS) score, ADL Scale Barthel Index (BI) score, the actual completion of the activities of daily living scale modified Rankin scale (MRS) score, serum lipids, blood rheology, vascular endothelial cell function testing.2 Part of Experimental:Rat model of focal cerebral ischemia, 40 male SD rats were randomly divided into Zhilong Huoxue Tongyu capsule Observer Group 10 cases, step Naoxintong positive control group and 10 cases, the model group 10 and 10 cases of sham-operated group, 7-day drug application TUNEL method and immunohistochemical detection of the rat brain and the distribution of apoptotic bcl-2, Caspase3 immunoreactive cells observation.Results: 1 Clinical results show that: After treatment observation group, the total efficiency of 93.33% in control group, the total efficiency of 76.67%, compared with the significant differences (P<0.01) after treatment groups CSS, NIHSS, BI, in varying degrees MRS score improvement Observer Group CSS and BI score improved significantly more than the control group (P<0.05) observed before and after treatment numbness, and awaking askew, dizziness dizzying, and visco-Tan Zhi, tongue and have significantly improved (P<0.01), the control group only numbness, dizziness dizzying, pulse 3 has improved (P <0.05), and the Observer Group in improving symptoms than the control group (P<0.05); Observer Group to reduce TC, TG, LDL-C, treatment and there is significant difference (P<0.01), and compared with the control group there were significant differences (P<0.05); Observer Group whole blood viscosity (high and low shear value), erythrocyte aggregation index, ESR and platelet aggregation and fibrinogen decreased significantly (P<0.01), and compared with the control group there were significant differences (P<0.01), vascular endothelial cell function testing of the two groups after treatment indicators have improved to varying degrees, Observer Group to endothelin (ET), thromboxane B2 (TXB2), plasminogen activator inhibitor-1 (PAI-1) was significantly reduced, and ET / NO ratio was significantly decreased, and TPA / PAI ratio was significantly higher (P<0.05,P<0.01), while the control group in ET, 6-F1a prostaglandin (6-keto-PGF1α), tissue plasminogen activator (TPA), PAI-1 had improved, but improved compared with the control group more obvious group (P<0.01) in the entire process of observation found no significant adverse events.2 The experimental results show that: Through DNA nick end labeling (TUNEL) confirmed acute cerebral ischemia and reperfusion in the presence of apoptotic cells. Model group neuronal apoptosis was significantly higher than the number of sham-operated group, Huoxue Tongyu group and Naoxintong drug intervention group compared with the model group apoptosis index decreased significantly (P<0.01), indicating Zhilong Huoxue Tongyu capsule and Step long Naoxintong capsule on the brain cells inhibit apoptosis. Immunohistochemistry was used to detect apoptosis gene bcl-2 protein expression and Caspase3 changes. Model group brain cells bc1-2 and Caspase-3 gene expression were significantly higher than the sham-operated group (P<0.01), compared with the model group, Huoxue Tongyu Naoxintong group and the group can enhance bc1-2 gene expression (P< 0.01) significantly inhibited Caspase-3 gene expression (P <0.01).Concusion: 1 Zhilong Huoxue Tongyu capsule treatment of patients with acute cerebral infarction more satisfied with the improvement of neurologic impairment score Syndrome effective than the control group, the main symptom improvement is better than the control group, serum lipid lowering efficacy superior to the control group, improving hemorrheology Indexes, effective than the control group, reversed secretion of vascular endothelial dysfunction, better than the control group. 2 cerebral infarction and neural cell apoptosis, Zhilong Huoxue Tongyu capsule on the treatment of acute cerebral ischemia may be inhibited by injury at the same time block Caspase-3 activation and inhibition of apoptosis alleviate neuronal apoptosis.